Citi lowered the firm’s price target on Evolent Health (EVH) to $9.50 from $11.50 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health: Overly Pessimistic Valuation Presents a Buy Opportunity Amidst Exaggerated Concerns
- Evolent Health price target lowered to $7 from $13 at JPMorgan
- Evolent Health price target lowered to $9 from $16 at Canaccord
- Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy Rating
- Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation Upside